Brokers Set Expectations for Decibel Therapeutics, Inc.’s FY2027 Earnings (NASDAQ:DBTX)

Decibel Therapeutics, Inc. (NASDAQ:DBTX – Get Rating) – Equities researchers at HC Wainwright issued their FY2027 earnings estimates for Decibel Therapeutics in a report issued on Wednesday, March 15th. HC Wainwright analyst J. Pantginis forecasts that the company will earn ($0.52) per share for the year. HC Wainwright currently has a “Buy” rating and a $23.00 target price on the stock. The consensus estimate for Decibel Therapeutics’ current full-year earnings is ($1.21) per share.

A number of other research firms also recently weighed in on DBTX. SVB Leerink downgraded Decibel Therapeutics from an “outperform” rating to a “market perform” rating and decreased their price objective for the company from $7.00 to $2.00 in a report on Wednesday. SVB Securities downgraded Decibel Therapeutics from an “outperform” rating to a “market perform” rating and decreased their price objective for the company from $7.00 to $2.00 in a report on Wednesday. Two analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $8.80.

Decibel Therapeutics Stock Performance

Shares of NASDAQ:DBTX opened at $3.73 on Thursday. The company has a fifty day moving average of $3.65 and a 200-day moving average of $3.48. The company has a market capitalization of $93.14 million, a PE ratio of -1.57 and a beta of -0.02. Decibel Therapeutics has a 52-week low of $1.61 and a 52-week high of $5.78.

Institutional Trading of Decibel Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of DBTX. Millennium Management LLC grew its holdings in Decibel Therapeutics by 54.0% during the 4th quarter. Millennium Management LLC now owns 488,783 shares of the company’s stock worth $1,002,000 after acquiring an additional 171,491 shares during the period. Point72 Asset Management L.P. acquired a new stake in Decibel Therapeutics during the 4th quarter worth about $184,000. Renaissance Technologies LLC grew its holdings in Decibel Therapeutics by 12.7% during the 4th quarter. Renaissance Technologies LLC now owns 36,394 shares of the company’s stock worth $75,000 after acquiring an additional 4,094 shares during the period. Geode Capital Management LLC grew its holdings in Decibel Therapeutics by 3.7% during the 4th quarter. Geode Capital Management LLC now owns 115,567 shares of the company’s stock worth $236,000 after acquiring an additional 4,170 shares during the period. Finally, Alphabet Inc. acquired a new stake in Decibel Therapeutics during the 3rd quarter worth about $5,661,000. 71.88% of the stock is currently owned by institutional investors and hedge funds.

About Decibel Therapeutics

(Get Rating)

Decibel Therapeutics, Inc, a clinical-stage biotechnology company, engages in discovering and developing transformative treatments for hearing and balance disorders. Its product candidates and programs focuses on three areas, such as Gene Therapies for Congenital, Monogenic Hearing Loss designed to restore functional cells within the cochlea to address hearing disorders caused by single gene mutations; Gene Therapies for Hair Cell Regeneration designed to replace lost hair cells within the inner ear to address acquired hearing loss and balance disorders; and Otoprotection Therapeutic in clinical development to prevent hearing loss in cancer patients undergoing chemotherapy with cisplatin.